Nicholas J Short1, Michael J Keating2, William G Wierda2, Stefan Faderl3, Alessandra Ferrajoli2, Zeev Estrov2, Susan C Smith2, Susan M O'Brien4. 1. Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Division of Leukemia, Hackensack University Medical Center, Hackensack, New Jersey. 4. Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, California.
Abstract
BACKGROUND: Fludarabine, cyclophosphamide, and rituximab (FCR) result in durable responses in patients with previously untreated chronic lymphocytic leukemia (CLL). Previous reports have suggested that in patients with relapsed CLL, a dose-intensified rituximab regimen increases response rates in comparison with standard-dose rituximab. It is unknown whether rituximab intensification of the FCR regimen will result in improved response rates and patient outcomes in patients with previously untreated CLL. METHODS: A single-arm study was conducted to evaluate the safety and efficacy of a modified FCR regimen with multiple-dose rituximab (FCR3) in 65 patients with previously untreated CLL. The results were compared with those for a historical cohort treated with FCR. RESULTS: The overall response rate to FCR3 was 97%, with 75% of the patients achieving a complete remission. Minimal residual disease negativity was achieved for 62% of the patients according to flow cytometry. The median time to progression (TTP) was 81 months, and the median overall survival (OS) was not reached, with 58% of the patients still alive at a median survivor follow-up of 9.7 years. Grade 3 or 4 neutropenia, grade 3 or 4 thrombocytopenia, and major infections were observed with 45%, 5%, and 1.9% of the FCR3 courses, respectively. Therapy-related myelodysplastic syndrome (t-MDS) or therapy-related acute myelogenous leukemia (t-AML) developed in 7 patients (11%; P < .01 vs the historical FCR cohort). CONCLUSIONS: In patients with previously untreated CLL, FCR3 resulted in response rates, TTP, and OS similar to those of a historical cohort of patients treated with FCR. FCR3 was associated with an increased incidence of t-MDS/t-AML.
BACKGROUND:Fludarabine, cyclophosphamide, and rituximab (FCR) result in durable responses in patients with previously untreated chronic lymphocytic leukemia (CLL). Previous reports have suggested that in patients with relapsed CLL, a dose-intensified rituximab regimen increases response rates in comparison with standard-dose rituximab. It is unknown whether rituximab intensification of the FCR regimen will result in improved response rates and patient outcomes in patients with previously untreated CLL. METHODS: A single-arm study was conducted to evaluate the safety and efficacy of a modified FCR regimen with multiple-dose rituximab (FCR3) in 65 patients with previously untreated CLL. The results were compared with those for a historical cohort treated with FCR. RESULTS: The overall response rate to FCR3 was 97%, with 75% of the patients achieving a complete remission. Minimal residual disease negativity was achieved for 62% of the patients according to flow cytometry. The median time to progression (TTP) was 81 months, and the median overall survival (OS) was not reached, with 58% of the patients still alive at a median survivor follow-up of 9.7 years. Grade 3 or 4 neutropenia, grade 3 or 4 thrombocytopenia, and major infections were observed with 45%, 5%, and 1.9% of the FCR3 courses, respectively. Therapy-related myelodysplastic syndrome (t-MDS) or therapy-related acute myelogenous leukemia (t-AML) developed in 7 patients (11%; P < .01 vs the historical FCR cohort). CONCLUSIONS: In patients with previously untreated CLL, FCR3 resulted in response rates, TTP, and OS similar to those of a historical cohort of patients treated with FCR. FCR3 was associated with an increased incidence of t-MDS/t-AML.
Authors: M Hallek; K Fischer; G Fingerle-Rowson; A M Fink; R Busch; J Mayer; M Hensel; G Hopfinger; G Hess; U von Grünhagen; M Bergmann; J Catalano; P L Zinzani; F Caligaris-Cappio; J F Seymour; A Berrebi; U Jäger; B Cazin; M Trneny; A Westermann; C M Wendtner; B F Eichhorst; P Staib; A Bühler; D Winkler; T Zenz; S Böttcher; M Ritgen; M Mendila; M Kneba; H Döhner; S Stilgenbauer Journal: Lancet Date: 2010-10-02 Impact factor: 79.321
Authors: Paolo Strati; Alessandra Ferrajoli; Susan Lerner; Susan O'Brien; William Wierda; Michael J Keating; Stefan Faderl Journal: Leuk Lymphoma Date: 2013-07-29
Authors: J C Byrd; T Murphy; R S Howard; M S Lucas; A Goodrich; K Park; M Pearson; J K Waselenko; G Ling; M R Grever; A J Grillo-Lopez; J Rosenberg; L Kunkel; I W Flinn Journal: J Clin Oncol Date: 2001-04-15 Impact factor: 44.544
Authors: Paolo Strati; Michael J Keating; Susan M O'Brien; Jan Burger; Alessandra Ferrajoli; Nitin Jain; Francesco Paolo Tambaro; Zeev Estrov; Jeffrey Jorgensen; Pramoda Challagundla; Stefan H Faderl; William G Wierda Journal: Blood Date: 2014-04-04 Impact factor: 22.113
Authors: Yi Zhou; Guilin Tang; L Jeffrey Medeiros; Timothy J McDonnell; Michael J Keating; William G Wierda; Sa A Wang Journal: Mod Pathol Date: 2011-11-11 Impact factor: 7.842
Authors: Sebastian Böttcher; Matthias Ritgen; Kirsten Fischer; Stephan Stilgenbauer; Raymonde M Busch; Günter Fingerle-Rowson; Anna Maria Fink; Andreas Bühler; Thorsten Zenz; Michael Karl Wenger; Myriam Mendila; Clemens-Martin Wendtner; Barbara F Eichhorst; Hartmut Döhner; Michael J Hallek; Michael Kneba Journal: J Clin Oncol Date: 2012-02-13 Impact factor: 44.544
Authors: Qiao Li; Xiangming Lao; Qin Pan; Ning Ning; Ji Yet; Yingxin Xu; Shengping Li; Alfred E Chang Journal: Clin Cancer Res Date: 2011-06-20 Impact factor: 12.531
Authors: Carmen D Herling; Kevin R Coombes; Axel Benner; Johannes Bloehdorn; Lynn L Barron; Zachary B Abrams; Tadeusz Majewski; Jolanta E Bondaruk; Jasmin Bahlo; Kirsten Fischer; Michael Hallek; Stephan Stilgenbauer; Bogdan A Czerniak; Christopher C Oakes; Alessandra Ferrajoli; Michael J Keating; Lynne V Abruzzo Journal: Lancet Oncol Date: 2019-09-30 Impact factor: 41.316
Authors: Candice Jamois; Ekaterina Gibiansky; Leonid Gibiansky; Vincent Buchheit; Denis Sahin; Guillaume Cartron; Robert Marcus; Wolfgang Hiddemann; John F Seymour; Jonathan C Strefford; Chantal E Hargreaves; Georgina Meneses-Lorente; Nicolas Frey; Günter Fingerle-Rowson Journal: Br J Clin Pharmacol Date: 2019-05-17 Impact factor: 4.335